Fero Foundation announces fourth edition of €70,000 grants for oncology research
The panel of judges, made up of doctors Carlos López Otín, Josep Baselga, among others, will select the best clinical science project or that with the most potential for clinical application.
By Biocat
The Foundation for Oncology Research (Fero), created in 2001 by Dr. Josep Baselga, has announced the fourth edition of their translational oncology research grants in Spain. The program aims to foster the training of young oncology researchers and allow scientific breakthroughs to reach cancer patients as soon as possible. Therefore, the panel of judges will recognize the best clinical science project or that with the most potential for clinical application.
The grant allocates €70,000 for a two-year research project. All those interested can submit their application through 30 April 2012.
Candidates must meet the following requirements:
- Be researchers that work in Spanish institutions involved in oncology research or treating cancer patients.
- Have focused their work on translational oncology research centering on clinical applications.
- Present a scientific project with clinical applications.
The panel of judges, presided over by professor Carlos López Otín, is made up of renowned experts from different areas of oncology, including doctors Joaquim Arribas, Josep Baselga, Andrés Cervantes, Luis Paz-Ares and Josep Tabernero. The verdict will be announced between 15 and 20 May 2012 and the awards will be presented on 4 June 2012 in Barcelona.
In 2011, 45 candidates presented their proposals, three times more than in the previous edition. The researchers that have been recognized so far are:
- Dr. Laura Soucek, head of the Mouse Models of Cancer Therapies Group at the Vall d’Hebron Institute of Oncology (VHIO), for inhibiting a protein involved in nearly all types of cancer.
- Dr. Amancio Carnero, focusing on translational sarcoma research.
- Dr. Jaume Mora Graupera, head of the Department of Oncology at Sant Joan de Déu Hospital in Barcelona, for a multicenter research and treatment study on the Ewing sarcoma family of tumors in children, adolescents and young adults.